Streetbeat News

Earnings

BZUN

DFAE

DFEM

Baozun Inc (NASDAQ: BZUN) reported a fiscal first-quarter 2024 revenue growth of 4.9% year-on-year to $274.2 million, beating analyst estimates. Despite an adjusted loss per ADS of $0.03, the stock price surged. The company saw increases in both product and services revenue. Baozun's stock has lost 32% in value over the last 12 months, but shares traded higher by 5.17% premarket. Investors can also gain exposure through Dimensional ETF Trust Dimensional Emerging Markets Core Equity 2 ETF (NYSE: DFEM) and Dimensional Emerging Core Equity Market ETF (NYSE: DFAE).

Portfolio Pulse from Anusuya Lahiri

May 28, 2024 | 11:33 am

DAC

Danaos Corporation (NYSE:DAC) reported Q1 2024 earnings per share (EPS) of $7.15, missing the analyst consensus estimate of $7.74 by 7.62%. The company also reported quarterly sales of $253.449 million, which missed the estimate of $256.000 million by 1.00%. Despite the misses, sales increased by 4.05% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 11:31 am

AAPL

AMC

BOX

CAVA

GME

NVDA

QQQ

SPY

Wall Street is expected to open slightly higher after the Memorial Day weekend, with tech and meme stocks showing gains. The SEC's transition from T+2 to T+1 settlement cycle aims to reduce trade risks. Key economic data and Fed speeches will influence market sentiment this week. Nvidia's earnings have boosted tech stocks, while GameStop and AMC saw significant premarket gains. Box and CAVA Group are set to report quarterly results after market close.

Portfolio Pulse from Shanthi Rexaline

May 28, 2024 | 11:27 am

ALKS

Alkermes plc (NASDAQ: ALKS) will present promising clinical data for its narcolepsy treatment, ALKS 2680, at the SLEEP 2024 conference. The presentations will include data from a Phase 1b study and the design of a Phase 2 study, as well as qualitative patient interviews.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 11:11 am

GLNG

Golar LNG (NASDAQ:GLNG) reported Q1 sales of $64.959 million, missing the analyst consensus estimate of $79.190 million by 17.97%. This represents a 12.18% decrease from the same period last year. The company exits the quarter with cash and equivalents worth $548 million.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 11:06 am

BLRX

BioLine Rx reported Q1 2024 GAAP EPS of $(0.00), which may not be comparable to the $(0.29) estimate. The company also reported sales of $6.855M, which may not be comparable to the $340.000K estimate.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 11:03 am

NVDA

SPY

USO

U.S. stock markets closed higher on Friday, driven by positive economic data and Nvidia's strong earnings. The Nasdaq marked its fifth consecutive weekly increase. In contrast, Asian and European markets dipped, while crude oil prices advanced towards $80 per barrel.

Portfolio Pulse from Akanksha Bakshi

May 28, 2024 | 10:40 am

ITRN

Ituran Location and Control Ltd. (ITRN) has reiterated its 2024 EBITDA expectations to be between $90M-$95M and targets 2025 EBITDA to surpass $100M. The company also expects to add 35,000 to 40,000 net new subscribers per quarter in 2024. These targets are based on current exchange rates and assume no significant worsening in the global macro-economic and political situation in Israel.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 10:37 am

GTHX

G1 Therapeutics, Inc. (NASDAQ:GTHX) announced positive Phase 2 clinical trial results showing improved overall survival (OS) and tolerability for patients receiving trilaciclib in combination with a TROP2 ADC (sacituzumab govitecan) compared to historical data from the ASCENT trial.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 10:35 am

ITRN

Ituran Location & Control (NASDAQ:ITRN) reported Q1 earnings per share (EPS) of $0.66, beating the analyst estimate of $0.59. However, sales of $85.03 million missed the estimate of $85.70 million.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 10:34 am